Boston, Mass., USA - Medicilon, a one-stop pharmaceutical preclinical R&D service platform CRO, recently appointed Liu Jian as the president of drug discovery division.
Article continues below
Dr. Liu Jian obtained his Ph.D. in Computational Chemistry and Organic Chemistry from the University of California, Los Angeles (UCLA), he subsequently conducted postdoctoral research at the University of California, Irvine, and the University of Pennsylvania.
In 2018, Dr. Liu Jian served as the President of the Sino-American Pharmaceutical Professionals Association (SAPA) and is currently the Chairman of the board of directors of SAPA.
In 2019, he was awarded the "Outstanding 50 Asian American in Business " by the Asian-American Business Development Center in New York and was elected as one of the 12 most influential Chinese-Americans in New Jersey.
With over 20 years of experience in innovative drug development, Dr. Liu Jian has led the team to invent 10 preclinical candidates (PCCs), which have entered Phase I, II, and III clinical trials.
He has filed over 72 patent applications, with 21 patents already granted.
Dr. Liu Jian also possesses profound academic achievements, having published a total of 47 articles in international academic journals and serving as a reviewer for several international academic journals.
Dr. Liu Jian joined the industry in 2001 and has worked for Merck for nearly 20 years.
He has led the R&D of novel small molecule drugs for various diseases, including osteoporosis, obesity, diabetes, cardiovascular disease, cancer, immune disease, antiviral and antibacterial, and pain.
Throughout his career, he progressed from Senior Research Chemist to Principal Scientist and External Discovery Chemistry Lead, receiving the "Merck Excellence Award" four times.
He later served as CSO and Operations Director at Jiangsu Hengrui Pharmaceutical USA Drug Discovery Center (EBI), leading the development of new drugs for cancer, immune diseases, osteoarthritis, and neurodegenerative diseases. ■